Slide 1: Interim report Q3 / 2024
Interim report Q3 / 2024 Vitrolife AB (publ) 24 October 2024 Bronwyn Brophy O´Connor, CEO Patrik Tolf, CFO
Slide 2: Q3/2024 Highlights
Q3/2024 Highlights Genetic services Growth Consumables North America +7%* +13%* +9%* 2 * Organic growth in local currencies
Slide 3: Improved growth with solid margins
Improved growth with solid margins Third quarter 2024 Sales Organic growth Gross margin 867 MSEK +7% 58.6% (848 MSEK) +2% in SEK In local currencies (55.7%) EBITDA Operating cash flow Earnings per share 289 MSEK 206 MSEK 0.85 SEK Margin 33.4% (33.9%) (214 MSEK) (0.90 SEK) First nine months 2024 Sales
Slide 4: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* +2% +9% +9% +7% Sales (MSEK) 273 328 266 867 Share of total sales 31% 38% 31% 4 * Organic growth in local currencies
Slide 5: Consumables business area
Consumables business area Strong momentum in all regions driven by media Net sales*, MSEK +10% 344 356 345 Organic growth** +13% 329 312 315 289 297 +9% +22% Americas EMEA +8% APAC Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 **in local currencies, Q3 2024 2022 2023 2024 5 *Excluding genomic kits in comparable numbers
Slide 6: Technologies business area
Technologies business area Continued progress in Time-lapse penetration Net sales, MSEK 206 9% Organic growth* 197 166 +11% 156 157 152 138 139 +11% +6% Americas EMEA +17% APAC Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 *in local currencies, Q3 2024 2022 2023 2024 6
Slide 7: Genetics business area
Genetics business area Core genetic services growing 5.5%, genomic kits declined by 26% Net sales*, MSEK 410 423 - 7% Organic growth** 401 0% 397 388 383 370 346 -1% -1% Americas EMEA +6% APAC Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 **in local currencies, Q3, 2024 2022 2023 2024 7 *Comparable numbers include genomi
Slide 8: Geographical segments
Geographical segments Americas EMEA APAC Total Sales (MSEK) 273 328 266 867 Gross income (MSEK) 144 198 167 508 Gross margin % 52.7% 60.4% 62.8% 58.6% Selling expenses (MSEK) -69 -73 -48 -190 Market contribution (MSEK) 75 125 119 319 Contribution margin % 27.5% 38.1% 44.7% 36.8% Contribution margin
Slide 9: Q3 financial highlights
Q3 financial highlights MSEK 848 867 +2% Net sales of SEK 867 million (848), +2% in SEK • Organic growth in local currencies +7% • Currency effect -5% primarily APAC and 508 473 Americas. Gross income of SEK 508 million (473) 287 289 • Margin of 58.6% (55.7%) • Positive product mix • Operational exce
Slide 10: Operating expenses
Operating expenses MSEK +14% Operating expenses 334 • Continue to invest in Sales and Marketing 294 capabilities in key markets • R&D expenses are slightly lower due to project phasing and capitalisation 190 • Other operating expenses are negatively 162 impacted by currency revaluation of working ca
Slide 11: Key financials
Key financials 2024 2023 2024 2023 Q3 Q3 Jan-Sep Jan-Sep Sales, MSEK 867 848 2,650 2,607 Gross Margin, % 58.6 55.7 58.6 56.1 EBITDA 289 287 888 842 EBITDA Margin, % 33.4 33.9 33.5 32.3 Net income 116 122 375 328 Earnings per share, SEK 0.85 0.90 2.76 2.42 Operating cash flow, MSEK 206 214 640 586 Net
Slide 12: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Labour Our values Market Growth in Consoli- Regionali- Patient and skills megatrends demand shortage dation sation Empowerment Integrity Vision with a purpose Long-term growth and profit-targets (5 years) ”Enable people to fulfil the dream of having a healthy baby” A
Slide 13: Focus for the rest of the year
Focus for the rest of the year Investment in commercial capabilities ongoing Increase share and penetration in the US Strengthen relationship with clinic chains through & China strategic account management (SAM) Maintain positive momentum in media Increase market share in Consumables Increas
Slide 14: Q/A
Q/A Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21
Slide 15: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there